AR and posterior cortical atrophy: While 22Rv1 cells, representing early-stage AR-positive PCa, show RNASET2 sensitivity, PC-3 cells, derived from aggressive, late-stage, AR-negative bone metastases, exhibit RNASET2 resistance [41].